Long-term outcomes of steroid therapy for Duchenne muscular dystrophy in Japan

Brain and Development

Volumn 38, Issue 9, 2016, Pages 785-791

  Goto, Masahide ^a   Komaki, Hirofumi ^a   Takeshita, Eri ^a   Abe, Yoshiki ^b   Ishiyama, Akihiko ^a   Sugai, Kenji ^a   Sasaki, Masayuki ^a   Goto, Yu ichi ^c   Nonaka, Ikuya ^c  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

Author keywords

Ambulation; Corticosteroid treatment; Height; Mixed model; Respiratory function; Side effect

Indexed keywords

PREDNISOLONE; CORTICOSTEROID; MUSCLE RELAXANT AGENT;

ADOLESCENT; ARTICLE; BEHAVIOR CHANGE; BODY HEIGHT; CHILD; CONFIDENCE INTERVAL; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; FEMALE; FORCED VITAL CAPACITY; FRACTURE; GAIT DISORDER; HAZARD RATIO; HEADACHE; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; JAPAN; MAJOR CLINICAL STUDY; MALE; MOBILIZATION; PRESCHOOL CHILD; REGRESSION ANALYSIS; RESPIRATORY FUNCTION; RETROSPECTIVE STUDY; SIDE EFFECT; STEROID THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; WEIGHT GAIN; BREATHING; DISABILITY; DRUG EFFECTS; FOLLOW UP; GENETICS; KAPLAN MEIER METHOD; MOTOR ACTIVITY; MUSCULAR DYSTROPHY, DUCHENNE; TIME FACTOR; VITAL CAPACITY;

ADOLESCENT; ADRENAL CORTEX HORMONES; BODY HEIGHT; CHILD; CHILD, PRESCHOOL; DISABILITY EVALUATION; FOLLOW-UP STUDIES; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; MOTOR ACTIVITY; MUSCULAR DYSTROPHY, DUCHENNE; NEUROMUSCULAR AGENTS; PREDNISOLONE; REGRESSION ANALYSIS; RESPIRATION; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84963985259     PISSN: 03877604     EISSN: 18727131     Source Type: Journal    
DOI: 10.1016/j.braindev.2016.04.001     Document Type: Article

References (29)

1. [1] Hutter, O.F., The membrane hypothesis of Duchenne muscular dystrophy: quest for functional evidence. J Inherit Metab Dis 15 (1992), 565–577.
2. [2] McDonald, C.M., Abresch, R.T., Carter, G.T., Fowler, W.M. Jr., Johnson, E.R., Kilmer, D.D., et al. Profiles of neuromuscular diseases. Duchenne muscular dystrophy. Am J Phys Med Rehabil 74 (1995), S70–S92.
3. [3] Drachman, D.B., Toyka, K.V., Myer, E., Prednisone in Duchenne muscular dystrophy. Lancet 2 (1974), 1409–1412.
4. [4] Manzur, A.Y., Kuntzer, T., Pike, M., Swan, A., Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev, 1, 2008, CD003725.
5. [5] Rahman, M.M., Hannan, M.A., Mondol, B.A., Bhoumick, N.B., Haque, A., Prednisolone in Duchenne muscular dystrophy. Bangladesh Med Res Counc Bull 27 (2001), 38–42.
6. [6] Mendell, J.R., Moxley, R.T., Griggs, R.C., Brooke, M.H., Fenichel, G.M., Miller, J.P., et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med 320 (1989), 1592–1597.
7. [7] Fenichel, G.M., Mendell, J.R., Moxley, R.T. 3rd, Griggs, R.C., Brooke, M.H., Miller, J.P., et al. A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy. Arch Neurol 48 (1991), 575–579.
8. [8] Pradhan, S., Ghosh, D., Srivastava, N.K., Kumar, A., Mittal, B., Pandey, C.M., et al. Prednisolone in Duchenne muscular dystrophy with imminent loss of ambulation. J Neurol 253 (2006), 1309–1316.
9. [9] Connolly, A.M., Schierbecker, J., Renna, R., Florence, J., High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy. Neuromuscul Disord 12 (2002), 917–925.
10. [10] Escolar, D.M., Hache, L.P., Clemens, P.R., Cnaan, A., McDonald, C.M., Viswanathan, V., et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology 77 (2011), 444–452.
11. [11] Biggar, W.D., Harris, V.A., Eliasoph, L., Alman, B., Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 16 (2006), 249–255.
12. [12] King, W.M., Ruttencutter, R., Nagaraja, H.N., Matkovic, V., Landoll, J., Hoyle, C., et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology 68 (2007), 1607–1613.
13. [13] Ricotti, V., Ridout, D.A., Scott, E., Quinlivan, R., Robb, S.A., Manzur, A.Y., et al. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry 84 (2013), 698–705.
14. [14] Moxley, R.T. 3rd, Ashwal, S., Pandya, S., Connolly, A., Florence, J., Mathews, K., et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 11:64 (2005), 13–20.
15. [15] Gloss, D., Moxley, R.T. 3rd, Ashwal, S., Oskoui, M., Practice guideline update summary: corticosteroid treatment of Duchenne muscular dystrophy: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 86 (2016), 465–472.
16. [16] Nishima, S., Flow-volume curve in healthy and asthmatic children in the non-attack stage (in Japanese). Rinsho to Kenkyu 54 (1977), 525–530.
17. [17] Miller, M.R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., et al. Standardisation of spirometry. Eur Respir J 26 (2005), 319–338.
18. [18] Cnaan, A., Laird, N.M., Slasor, P., Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data. Stat Med 16 (1997), 2349–2380.
19. [19] Griggs, R.C., Herr, B.E., Reha, A., Elfring, G., Atkinson, L., Cwik, V., et al. Corticosteroids in Duchenne muscular dystrophy: major variations in practice. Muscle Nerve 48 (2013), 27–31.
20. [20] Hoffman, E.P., Reeves, E., Damsker, J., Nagaraju, K., McCall, J.M., Connor, E.M., et al. Novel approaches to corticosteroid treatment in Duchenne muscular dystrophy. Phys Med Rehabil Clin N Am 23 (2012), 821–828.
21. [21] Moxley, R.T. 3rd, Pandya, S., Ciafaloni, E., Fox, D.J., Campbell, K., Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J Child Neurol 25 (2010), 1116–1129.
22. [22] Henricson, E.K., Abresch, R.T., Cnaan, A., Hu, F., Duong, T., Arrieta, A., et al. The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures. Muscle Nerve 48 (2013), 55–67.
23. [23] Mayer, O.H., Finkel, R.S., Rummey, C., Benton, M.J., Glanzman, A.M., Flickinger, J., et al. Characterization of pulmonary function in Duchenne Muscular Dystrophy. Pediatr Pulmonol 50 (2015), 487–494.
24. [24] Nève, V., Cuisset, J.M., Edmé, J.L., Carpentier, A., Howsam, M., Leclerc, O., et al. Sniff nasal inspiratory pressure in the longitudinal assessment of young Duchenne muscular dystrophy children. Eur Respir J 42 (2013), 671–680.
25. [25] Bonifati, M.D., Ruzza, G., Bonometto, P., Berardinelli, A., Gorni, K., Orcesi, S., et al. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve 23 (2000), 1344–1347.
26. [26] Backman, E., Henriksson, K.G., Low-dose prednisolone treatment in Duchenne and Becker muscular dystrophy. Neuromuscul Disord 5 (1995), 233–241.
27. [27] Practical Guideline for Duchenne Muscular Dystrophy Working Group, (eds.) Practical guideline for duchenne muscular dystrophy (DMD), 2014, Nankodo Co., Ltd, Tokyo [in Japanese].
28. [28] Nakamura, H., Kimura, E., Mori-Yoshimura, M., Komaki, H., Matsuda, Y., Goto, K., et al. Characteristics of Japanese Duchenne and Becker muscular dystrophy patients in a novel Japanese national registry of muscular dystrophy (Remedy). Orphanet J Rare Dis, 8, 2013, 60.
29. [29] Takeuchi, F., Yonemoto, N., Nakamura, H., Shimizu, R., Komaki, H., Mori-Yoshimura, M., et al. Prednisolone improves walking in Japanese Duchenne muscular dystrophy patients. J Neurol 260 (2013), 3023–3029.